- Home
- DHI vs ALNY Comparison
DHI vs ALNY Comparison
Compare DHI & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHI
- ALNY
- Stock Information
- Founded
- DHI 1978
- ALNY 2002
- Country
- DHI United States
- ALNY United States
- Employees
- DHI N/A
- ALNY N/A
- Industry
- DHI Homebuilding
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- DHI Consumer Discretionary
- ALNY Health Care
- Exchange
- DHI Nasdaq
- ALNY Nasdaq
- Market Cap
- DHI 51.3B
- ALNY 59.6B
- IPO Year
- DHI 1992
- ALNY 2004
- Fundamental
- Price
- DHI $181.02
- ALNY $468.58
- Analyst Decision
- DHI Buy
- ALNY Strong Buy
- Analyst Count
- DHI 15
- ALNY 28
- Target Price
- DHI $165.57
- ALNY $424.22
- AVG Volume (30 Days)
- DHI 3.7M
- ALNY 1.2M
- Earning Date
- DHI 10-28-2025
- ALNY 10-30-2025
- Dividend Yield
- DHI 0.88%
- ALNY N/A
- EPS Growth
- DHI N/A
- ALNY N/A
- EPS
- DHI 12.48
- ALNY N/A
- Revenue
- DHI $34,575,200,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- DHI N/A
- ALNY $58.97
- Revenue Next Year
- DHI $1.47
- ALNY $38.81
- P/E Ratio
- DHI $14.50
- ALNY N/A
- Revenue Growth
- DHI N/A
- ALNY 5.01
- 52 Week Low
- DHI $110.44
- ALNY $205.87
- 52 Week High
- DHI $199.85
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- DHI 67.71
- ALNY 66.84
- Support Level
- DHI $174.30
- ALNY $444.66
- Resistance Level
- DHI $184.55
- ALNY $484.21
- Average True Range (ATR)
- DHI 4.23
- ALNY 12.68
- MACD
- DHI 0.07
- ALNY -2.06
- Stochastic Oscillator
- DHI 85.00
- ALNY 63.40
About DHI D.R. Horton Inc.
With operations in 126 markets across 36 states D.R. Horton is the leading homebuilder in the United States. D.R. Horton mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.